Remacemide
Based on 1 Customer Validation
Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of hypoxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 128298-28-2
- Fòrmula: C17H20N2O
- Peso molecular:268.35
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Neuronal Signaling Compound Library
HY-L013
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neuroprotective Compound Library
HY-L070
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Antidepressant Compound Library
HY-L108
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Ion Channel Compound Library
HY-L166
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Ver todos los productos específicos de isoformas iGluR
More
Actividad biológica
|
NMDA Receptor |
Chemical Information
-
No. CAS 128298-28-2
-
Appearance Solid
-
Peso molecular 268.35
-
Fòrmula C17H20N2O
-
SMILES
O=C(CN)NC(C)(CC1=CC=CC=C1)C2=CC=CC=C2
-
Synonyms
FPL 12924; PR 934-423; FPL 13592
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
DMSO : 87.5 mg/mL (326.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (271 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Schachter SC, et al. Remacemide: current status and clinical applications. Expert Opin Investig Drugs. 2000 Apr;9(4):871-83. [Content Brief]
[2]. Dyker AG, et al. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke. 1999 Sep;30(9):1796-801. [Content Brief]
[3]. Greenamyre JT, et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol. 1994 Jun;35(6):655-61. [Content Brief]
[4]. Kieburtz K, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord. 1996 May;11(3):273-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7265 mL | 18.6324 mL | 37.2648 mL | 93.1619 mL |
| 5 mM | 0.7453 mL | 3.7265 mL | 7.4530 mL | 18.6324 mL | |
| 10 mM | 0.3726 mL | 1.8632 mL | 3.7265 mL | 9.3162 mL | |
| 15 mM | 0.2484 mL | 1.2422 mL | 2.4843 mL | 6.2108 mL | |
| 20 mM | 0.1863 mL | 0.9316 mL | 1.8632 mL | 4.6581 mL | |
| 25 mM | 0.1491 mL | 0.7453 mL | 1.4906 mL | 3.7265 mL | |
| 30 mM | 0.1242 mL | 0.6211 mL | 1.2422 mL | 3.1054 mL | |
| 40 mM | 0.0932 mL | 0.4658 mL | 0.9316 mL | 2.3290 mL | |
| 50 mM | 0.0745 mL | 0.3726 mL | 0.7453 mL | 1.8632 mL | |
| 60 mM | 0.0621 mL | 0.3105 mL | 0.6211 mL | 1.5527 mL | |
| 80 mM | 0.0466 mL | 0.2329 mL | 0.4658 mL | 1.1645 mL | |
| 100 mM | 0.0373 mL | 0.1863 mL | 0.3726 mL | 0.9316 mL |
Remacemide Related Classifications
HY-160604 Related Classifications
Powered by Bioz